BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22450349)

  • 1. Atypical, invasive, recurring Crooke cell adenoma of the pituitary.
    Rotondo F; Cusimano M; Scheithauer BW; Coire C; Horvath E; Kovacs K
    Hormones (Athens); 2012; 11(1):94-100. PubMed ID: 22450349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
    Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
    Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory pituitary adenoma: a novel classification for pituitary tumors.
    Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R
    Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
    Moshkin O; Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Uribe H; Gonzalez R; Cusimano M; Horvath E; Rotondo F; Kovacs K
    Hormones (Athens); 2011; 10(2):162-7. PubMed ID: 21724542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
    Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
    J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
    Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
    Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
    Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of temozolomide in aggressive pituitary tumors: case report.
    Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
    Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary atypical adenoma or carcinoma sensitive to temozolomide combined with radiation therapy: a case report of early identification and management.
    Zhong C; Yin S; Zhou P; Jiang S
    Turk Neurosurg; 2014; 24(6):963-6. PubMed ID: 25448217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
    Ceccato F; Lombardi G; Manara R; Emanuelli E; Denaro L; Milanese L; Gardiman MP; Bertorelle R; Scanarini M; D'Avella D; Occhi G; Boscaro M; Zagonel V; Scaroni C
    J Neurooncol; 2015 Mar; 122(1):189-96. PubMed ID: 25555563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
    Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
    J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
    Matsuno A; Murakami M; Hoya K; Yamada SM; Miyamoto S; Yamada S; Son JH; Nishido H; Ide F; Nagashima H; Sugaya M; Hirohata T; Mizutani A; Okinaga H; Ishii Y; Tahara S; Teramoto A; Osamura RY
    Med Mol Morphol; 2014 Mar; 47(1):1-7. PubMed ID: 23955641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.
    Ghazi AA; Rotondo F; Kovacs K; Amirbaigloo A; Syro LV; Fathalla H; Di Ieva A; Cusimano MD
    Endocr Pathol; 2015 May; 26(2):135-9. PubMed ID: 25716461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of pituitary neoplasms with temozolomide: a review.
    Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
    Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for early chemotherapy in the management of pituitary adenomas?
    Lin AL; Sum MW; DeAngelis LM
    Neuro Oncol; 2016 Oct; 18(10):1350-6. PubMed ID: 27106409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.
    Saeger W; Lüdecke DK; Buchfelder M; Fahlbusch R; Quabbe HJ; Petersenn S
    Eur J Endocrinol; 2007 Feb; 156(2):203-16. PubMed ID: 17287410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
    Donovan LE; Arnal AV; Wang SH; Odia Y
    CNS Oncol; 2016 Oct; 5(4):203-9. PubMed ID: 27615706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide in aggressive pituitary adenomas and carcinomas.
    Ortiz LD; Syro LV; Scheithauer BW; Rotondo F; Uribe H; Fadul CE; Horvath E; Kovacs K
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):119-23. PubMed ID: 22584716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician.
    Gomez-Hernandez K; Ezzat S; Asa SL; Mete Ö
    Turk Patoloji Derg; 2015; 31 Suppl 1():4-17. PubMed ID: 26177314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification and pathology of pituitary tumors.
    Kontogeorgos G
    Endocrine; 2005 Oct; 28(1):27-35. PubMed ID: 16311407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.